|Bid||1.2600 x 2900|
|Ask||1.3000 x 1200|
|Day's Range||1.2600 - 1.3000|
|52 Week Range||1.1500 - 8.8800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
JW-300 Demonstrates Efficacy in Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo Controlled Clinical Trial.JUPITER, FL / ACCESSWIRE / November 16, 2021 / Jupiter Wellness, Inc.
JUPITER, FL / ACCESSWIRE / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.
AI in medicine is projected to grow 18X from 2018 through 2025 to $35 billionJUPITER, FL / ACCESSWIRE / November 3, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that it has filed a registration statement with the Securities and Exchange Commission to sponsor Jupiter Wellness Acquisition Corp.